Tag - MIRO

Developments

Miromatrix, CareDx in pact for bioengineered organs in human transplant

Miromatrix Medical (NASDAQ:MIRO) and CareDx (NASDAQ:CDNA) entered an exclusive partnership aimed at advancing the next wave of innovation using fully transplantable human bioengineered organs. CareDx will develop an...

April 5, 2023

Developments

Miromatrix to respond to FDA clinical hold on miroliverELAP in second half

Miromatrix Medical (NASDAQ:MIRO) has evaluated a clinical hold on its investigational miroliverELAP transplantable organ and plans to submit its response to the FDA in the second half of 2023 and initiate a first-in...

February 1, 2023

Feature

Miromatrix bioengineering human organs to eliminate waitlists

With the need for organs for transplantation far exceeding the supply and creating long waitlists, Miromatrix Medical (NASDAQ:MIRO) is bioengineering human organs with the potential to eliminate the transplant waitlists.

November 8, 2022

Markets

Piper starts Miromatrix Medical at OW; PT $8

Piper Sandler launched coverage of Miromatrix Medical (NASDAQ:MIRO) with an “overweight” rating and $8 price target. The stock closed at $2.92 on Aug. 30. Miromatrix has developed a proprietary perfusion technology...

August 31, 2022

Tag - MIRO

Miromatrix, CareDx in pact for bioengineered organs in human transplant

Miromatrix to respond to FDA clinical hold on miroliverELAP in second half

Miromatrix bioengineering human organs to eliminate waitlists

Piper starts Miromatrix Medical at OW; PT $8

General

More